Timpani Capital Management’s iRadimed IRMD Stock Holding History

Timpani Capital Management’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$963K	Sell	34,288 -7,364	-18%	-$193K	0.46%	76
2018 Q4	$1.02M	Sell	41,652 -4,955	-11%	-$133K	0.57%	66
2018 Q3	$1.73M	Buy	46,607 +11,052	+31%	+$298K	0.5%	68
2018 Q2	$738K	Buy	+35,555	New	+$628K	0.22%	90
2016 Q3	–	Sell	-74,936	Closed	-$1.63M	–	89
2016 Q2	$1.63M	Sell	74,936 -47,758	-39%	-$859K	0.69%	59
2016 Q1	$2.35M	Buy	122,694 +23,039	+23%	+$441K	0.99%	48
2015 Q4	$2.79M	Buy	+99,655	New	+$2.82M	1.13%	39

Other funds holding IRMD

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

CCM

Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return

RCMC

RK Capital Management (Colorado) Denver, Colorado $324K AUM 47.52% 1-Year Est. Return

Navellier & Associates Reno, Nevada $960M AUM 79.37% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Timpani Capital Management's IRMD Position: Q1 2019 in Review

Timpani Capital Management reduced its iRadimed (IRMD) stake by 18% in Q1 2019, selling an estimated $193K and leaving 34,288 shares worth $963K. The position accounts for 0.46% of the portfolio, ranked #76.

Timpani Capital Management first reported a position in IRMD in Q4 2015 and has held it in 7 quarters since. The position peaked at $2.79M in Q4 2015. 64 funds tracked by Wall St. Rank hold IRMD as of Q1 2019.

Timpani Capital Management held 34,288 shares of iRadimed worth $963K as of Q1 2019.
Timpani Capital Management sold 7,364 iRadimed shares in Q1 2019, an estimated $193K.
iRadimed made up 0.46% of Timpani Capital Management's portfolio in Q1 2019, its #76 holding.
Timpani Capital Management first reported a position in iRadimed in Q4 2015 and has held it in 7 quarters since.
Timpani Capital Management's iRadimed position peaked at $2.79M in Q4 2015.
64 funds tracked by Wall St. Rank held iRadimed as of Q1 2019.

Based on Timpani Capital Management's 13F filing for Q1 2019, filed 10 May 2019.